Can a supplement replace HRT? The honest research answer

By The Krevie Team  |  Last reviewed: April 2026

No. HRT replaces hormones directly; food supplements do not. They operate through different biological mechanisms, are made from different raw materials, and are regulated under entirely different legal frameworks. Supplements are not medicine. If HRT is a live question for you, your GP is the right person to discuss it with.

That is the honest answer — and it matters enough to state it plainly before anything else. The question of whether supplements can replace HRT comes up constantly in online forums, and it deserves a clear, research-grounded response rather than a vague non-answer.

This article explains what separates these two categories mechanistically and evidentially, what the research does and does not show about each, and where a research-based nutritional routine fits within that picture.

What HRT is — and what supplements are

HRT (hormone therapy) is a prescription medicine. It works by supplying exogenous hormones — typically oestrogen, progesterone, or both — to compensate for the decline in endogenous hormone production that occurs during perimenopause and menopause. HRT binds directly to oestrogen receptors throughout the body. This is what produces its documented effects on bone, the cardiovascular system, and certain other systems.

Food supplements are a completely different legal category. In the United Kingdom, they are regulated as food under the Food Supplements (England) Regulations 2003 and the Food Safety Act 1990. They are not authorised to treat, cure, or prevent any medical condition. They cannot make disease claims. They cannot be marketed as alternatives to prescription medication.

This is not a loophole or a technicality. It reflects a genuine mechanistic reality: food supplements provide vitamins, minerals, botanical extracts, amino acids, and related compounds that support the body's normal physiological processes. They do not replace hormones. They do not activate or modulate the oestrogen receptor system. These are different biological pathways, full stop.

The supplement industry has muddied this by using phrases implying hormone-therapy equivalence or "hormone balance" — framings that are both legally non-compliant and scientifically inaccurate. An honest assessment has to start by separating these categories clearly.

What the research shows

HRT: the evidence base

HRT has a robust evidence base for specific outcomes, built through large randomised controlled trials.

Bone density. The PEPI trial (The Writing Group for the PEPI, JAMA, 1996; PubMed 8892713) enrolled postmenopausal women in a 36-month randomised placebo-controlled study. Women assigned to oestrogen-based active regimens gained an average of 3.5–5.0% in spinal bone mineral density, compared with a loss of 1.8% in the placebo group. Hip bone mineral density also increased. This is a well-replicated finding: HRT maintains bone mineral density through direct modulation of the osteoclast/osteoblast system via oestrogen receptor signalling.

Vasomotor measures. This is where HRT has its strongest and most consistent evidence. Multiple large RCTs have consistently demonstrated reductions in vasomotor event frequency compared with placebo. This is the outcome most widely cited in clinical guidance and the primary licensed indication for HRT in the UK.

Cognition: a more complex picture. The cognitive evidence for HRT is considerably less clear. The Kronos Early Estrogen Prevention Study Cognitive and Affective sub-study (KEEPS-Cog; Gleason et al., PLOS ONE, 2015; PubMed 26035291) found that, for recently postmenopausal women, menopausal hormone therapy did not significantly alter cognitive performance compared with placebo across a four-year period. The KEEPS Continuation Study (Kantarci et al., PLOS Medicine, 2024; PubMed 39570992), which followed the same cohort approximately ten years after the original trial, confirmed no long-term cognitive benefit or harm from menopausal hormone therapy initiated in early menopause. The conclusion of the KEEPS Continuation authors was direct: "mHT should not be recommended as an intervention to preserve cognitive function in postmenopausal women."

The "critical window hypothesis" — the idea that HRT must be started close to menopause onset to confer cognitive benefit — remains theoretically compelling but has not been confirmed in definitive prospective trials. It is a hypothesis, not an established finding.

Research-backed supplements: a different evidence framework

The key point is that supplements are not tested against HRT. They are tested in their own RCTs, measuring their own outcomes through their own mechanisms. The evidence base is assessed on those terms — not as a comparison to hormone therapy.

Creatine HCl — CONCRET-MENOPA trial (Forbes et al., Journal of the American Nutrition Association, 2025; PubMed 40854087). This randomised double-blind placebo-controlled trial enrolled 36 perimenopausal and menopausal women. The medium-dose creatine HCl group (1,500mg/day) showed a 6.6% improvement in reaction time versus 1.2% in placebo (p<0.01), and a 16.4% increase in frontal brain creatine levels versus 0.9% in placebo (p<0.01), over eight weeks. Creatine works via cellular energy metabolism — specifically the phosphocreatine system — not via any hormonal mechanism.

pine bark — Yang et al. (Acta Obstet Gynecol Scand, 2007; PubMed 17653885). A randomised double-blind placebo-controlled trial in 155 perimenopausal women using 200mg pine bark daily. All measured climacteric symptom scores improved relative to placebo. Antioxidative status increased and the LDL/HDL ratio improved. pine bark's proposed mechanism involves nitric oxide synthesis and antioxidant activity — again, not hormonal signalling.

pine bark — Luzzi et al. (Minerva Ginecol, 2017; PubMed 28116886). In 35 perimenopausal women using 100mg/day over eight weeks, plasma free radicals dropped by 22%, homocysteine decreased by 43%, and CRP decreased by 60% (all p<0.05). No equivalent cardiovascular markers are primary outcomes in HRT trials — these are nutritional pathways, not hormonal ones.

Citicoline — Silveri, Dikan, Ross et al. (NMR in Biomedicine, 2008; PubMed 18816480). In 16 healthy adults with mean age 47, six weeks of citicolineat 500mg produced a 7% increase in phosphocreatine, a 14% increase in beta-nucleoside triphosphates (largely ATP in the brain), and a 32% increase in the ratio of phosphocreatine to inorganic phosphate in the anterior cingulate cortex. These are measures of cellular bioenergetics, not hormone levels.

The pattern is consistent: these ingredients have RCT evidence for specific, measurable outcomes through nutritional and metabolic mechanisms. None of those mechanisms are oestrogen replacement. None of those trials position the supplement as a HRT comparator, because that framing is scientifically incoherent.

How this relates to Krevie

Krevie's position is not that supplements substitute for hormone therapy. The position is that high-quality nutritional support — with ingredients that match the doses used in published clinical trials — is something women can use alongside whatever medical pathway is right for them.

The Krevie Routine contains The Foundation and Creatine Companion. The Foundation includes citicoline as citicoline (500mg), pine bark (200mg — matching the Yang et al. 2007 trial dose), saffron extract (28mg daily), vitamin D3 (2,000 IU), and vitamin K2 as MK-7 (100mcg). Creatine Companion provides creatine HCl at 1,500mg — the medium dose used in the CONCRET-MENOPA trial. Every dose matches a published research study.

None of these ingredients replaces hormones. That is not their purpose. What the research shows is that they support specific nutritional and metabolic pathways that are distinct from — and not in competition with — hormonal therapy.

If you are on HRT, The Krevie Routine can sit alongside it. If you are not on HRT — whether by choice, contraindication, or circumstance — these ingredients have their own evidence base that is independent of HRT status. The CONCRET-MENOPA trial, for example, did not exclude women on hormone therapy; the two approaches work through different pathways and do not interact.

The Krevie Routine is priced at £49 for the first month, £75 recurring.

On HRT specifically: Krevie does not provide medical advice. If you are considering HRT, considering stopping it, or trying to decide whether it is appropriate for your situation, those decisions belong with your GP or a specialist menopause clinician. The NICE guideline NG23 on menopause is a useful reference, and your GP can access it. Food supplements are not medicine and cannot substitute for that conversation.

Frequently asked questions

Further reading

• Taking creatine alongside HRT: what the research says about combining them
• HRT and cognitive changes in perimenopause: what the research does and doesn't show
• What "clinically dosed" actually means — and how to check

References

1. The Writing Group for the PEPI. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA. 1996;276(17):1389–96. PubMed 8892713
2. Gleason CE, Dowling NM, Wharton W, et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS–Cognitive and Affective Study. PLOS ONE. 2015. PubMed 26035291
3. Kantarci K, Tosakulwong N, Lesnick TG, et al. Long-term cognitive effects of menopausal hormone therapy. PLOS Medicine. 2024. PubMed 39570992
4. Korovljev D, Ostojic J, Panic J, et al. The Effects of 8-Week Creatine Hydrochloride and Creatine Ethyl Ester Supplementation on Cognition, Clinical Outcomes, and Brain Creatine Levels in Perimenopausal and Menopausal Women (CONCRET-MENOPA). J Am Nutr Assoc. 2025. PubMed 40854087
5. Yang HM, Liao MF, Zhu SY, Liao MN, Rohdewald P. A randomised, double-blind, placebo-controlled trial on the effect of pine bark on the climacteric syndrome in peri-menopausal women. Acta Obstet Gynecol Scand. 2007;86(8):978–85. PubMed 17653885
6. Luzzi R, Belcaro G, Hosoi M, et al. Normalization of cardiovascular risk factors in peri-menopausal women with pine bark. Minerva Ginecol. 2017. PubMed 28116886
7. Silveri MM, Dikan J, Ross AJ, et al. Citicoline enhances frontal lobe bioenergetics as measured by phosphorus magnetic resonance spectroscopy. NMR Biomed. 2008;21(10):1066–75. PubMed 18816480